Related Experiment Video

Updated: Jul 10, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Analysis of associations of NAT2 gene polymorphisms with the risk of lung cancer

M V Nikishina1, V A Vavilin, S I Makarova

  • 1Institute of Molecular Biology and Biophysics, Siberian Division of Russian Academy of Medical Sciences, Novosibirsk. mnikishina@rambler.ru

Bulletin of Experimental Biology and Medicine
|November 21, 2007
PubMed

Insights

Genetic variations in the N-acetyltransferase-2 (NAT2) gene influence lung cancer risk. Specifically, the A803G polymorphism may offer resistance to lung cancer in Caucasian smokers. Different NAT2 gene variations might have opposing effects on cancer risk.

Area of Science:

  • Genetics
  • Oncology
  • Pharmacogenomics

Background:

  • Lung cancer remains a leading cause of cancer-related mortality worldwide.
  • Genetic factors, including variations in drug-metabolizing enzymes, play a role in cancer susceptibility.
  • The N-acetyltransferase-2 (NAT2) gene is involved in the metabolism of various xenobiotics, including carcinogens found in tobacco smoke.

Purpose of the Study:

  • To investigate the association between five polymorphisms of the N-acetyltransferase-2 (NAT2) gene and the risk of developing lung cancer.
  • To identify specific NAT2 gene variants that may confer resistance or susceptibility to lung cancer in a Caucasian population in Novosibirsk.

Main Methods:

  • Genotyping of five N-acetyltransferase-2 (NAT2) gene polymorphisms in patients diagnosed with lung cancer and control subjects.
  • Statistical analysis to evaluate the incidence of these polymorphisms and their correlation with lung cancer risk, considering smoking status and ethnicity.

Main Results:

  • The study identified that the A803G polymorphism of the NAT2 gene is associated with a reduced risk of lung cancer in Caucasian smokers from Novosibirsk.
  • Evidence suggests that different polymorphisms within the NAT2 gene may exert opposing effects on an individual's susceptibility to lung cancer.

Conclusions:

  • The A803G polymorphism of the NAT2 gene appears to be a protective factor against lung cancer in a specific population subgroup (tobacco-smoking Caucasians in Novosibirsk).
  • The findings highlight the complex and potentially differential roles of NAT2 gene polymorphisms in modulating lung cancer risk, warranting further investigation.

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...